Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma

PURPOSE: Immunologic targeting of tumor-specific gene mutations may allow precise eradication of neoplastic cells without toxicity. Epidermal growth factor receptor variant III (EGFRvIII) is a constitutively activated and immunogenic mutation not expressed in normal tissues but widely expressed in g...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Sampson, John H., Heimberger, Amy B., Archer, Gary E., Aldape, Kenneth D., Friedman, Allan H., Friedman, Henry S., Gilbert, Mark R., Herndon, James E., McLendon, Roger E., Mitchell, Duane A., Reardon, David A., Sawaya, Raymond, Schmittling, Robert J., Shi, Weiming, Vredenburgh, James J., Bigner, Darell D.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Clinical Oncology 2010
Matèries:
Original Reports
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3020702/
https://ncbi.nlm.nih.gov/pubmed/20921459
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2010.28.6963
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars